For instance, an association was reported between Treg-mediated suppression of tumor-specific CD4+ T cells prior to surgery and tumor recurrence in CRC patients at 12 months [59], whereas FOLFIRI (levo-leucovorin, 5-fluorouracil, irinotexan)- bevacizumab therapy of metastatic CRC patients was associated with better clinical outcome, but also with reduced numbers of circulating Treg [60, 61]. The gene discussed is CD4; the disease is colorectal carcinoma.